Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials-Reference-Cited by-同舟云学术

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Published:2015-02 Issue:2 Volume:16 Page:141-151
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Yang James Chih-Hsin,Wu Yi-Long,Schuler Martin,Sebastian Martin,Popat Sanjay,Yamamoto Nobuyuki,Zhou Caicun,Hu Cheng-Ping,O'Byrne Kenneth,Feng Jifeng,Lu Shun,Huang Yunchao,Geater Sarayut L,Lee Kye Young,Tsai Chun-Ming,Gorbunova Vera,Hirsh Vera,Bennouna Jaafar,Orlov Sergey,Mok Tony,Boyer Michael,Su Wu-Chou,Lee Ki Hyeong,Kato Terufumi,Massey Dan,Shahidi Mehdi,Zazulina Victoria,Sequist Lecia V

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Treating patients with EGFR-sensitizing mutations: first line or second line-is there a difference?;Mok;J Clin Oncol,2013

2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

Cited by 1385 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysis;2024-09-11

2. Novel Combination of Therapeutic Approaches in Advanced NSCLC with EGFR Activating Mutations;Targets;2024-09-07

3. Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study;Frontiers in Pharmacology;2024-09-06

4. Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors;Future Oncology;2024-09-04

5. Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung Adenocarcinoma;JTO Clinical and Research Reports;2024-09